Biopharmaceuticals are mainly: recombinant proteins, monoclonal antibodies,
products derived from nucleic acids and products derived from cells and tissues. The
first product was humulin, released 28 years ago. There are 200 biopharmaceuticals
approved for use in humans, and all but 2 are proteins. The global market value is close
to 100 billion dollars, but there are 2000 products in development process which have
not been released yet. As only 0.1% of the products released for human uses are derived
from secondary metabolism metabolites, we may clearly notice that even among the
2000 products under development, only a small fraction belongs to the secondary
metabolism group. Actually, the biotech pipelines overwhelmed by proteins. The Brazilian
Biodiversity (Fig. 1) reserves this space among the biopharmaceuticals to toxins and
poisons from reptiles, amphibians and insects, besides various microorganisms and
substances from the marine biome. The following analysis, though, describes important
adjustments, which are necessary, regarding the laws that regulate access to biodiversity
and the patent law.
Keywords: Biopharmaceutical Blockbusters, The Good Law for Innovation, The
Subvention law, Biomes - The Amazon Forest, The Caatinga, The Atlantic Forest,
The Pantanal, The Cerrado, The Pampas, RENORBIO, The National Institutes
for Science and Technology, ALANAC, INTERFARMA, Acheflan, UFC
Pharmaceutical Research and Development Center, UFC’s National Laboratory of
Experimental Oncology (LOE), Plants, Microorganisms.
